· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 25, 2005
The following updated safety information has been provided recently to healthcare professionals to review with their patients when prescribing Aranesp®.
Aranesp® has been approved in Canada since 2002 for the treatment of anemia in patients with chronic renal failure (CRF). Recently, cases of pure red cell aplasia (PRCA) have been reported from post-marketing experience in patients treated with Aranesp®. PRCA is a condition, in which a patient's bone marrow stops producing red blood cells, leading to severe anemia. This condition has also been observed following treatment with other similar medications (known as erythropoiesis-stimulating proteins). Patients who develop PRCA may experience a new or worsening feeling of tiredness or shortness of breath.
Should a patient being treated with Aranesp® experience symptoms of PRCA, they should immediately contact their doctor. There could be several reasons that may explain these symptoms that a doctor may investigate. Patients should NOT discontinue their medication without contacting their doctor first. Patients who have previously experienced PRCA with the use of any similar medication, should tell their doctor prior to beginning any treatment as they should not receive Aranesp® or any other erythropoiesis-stimulating proteins.
Should you have any questions or require further information regarding the use of Aranesp®, please contact Amgen Medical Information at 1-866-502-6436.
Amgen Canada Inc.
6755 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 7Y2
Tel: 1-866-502-6436
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738